<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1FE9B7FF-1274-4320-ADE0-4E18B9D24C59"><gtr:id>1FE9B7FF-1274-4320-ADE0-4E18B9D24C59</gtr:id><gtr:name>Makerere University College of Health Sciences</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1FE9B7FF-1274-4320-ADE0-4E18B9D24C59"><gtr:id>1FE9B7FF-1274-4320-ADE0-4E18B9D24C59</gtr:id><gtr:name>Makerere University College of Health Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/96D43A36-8970-46E6-8DF4-0FA40E944EFC"><gtr:id>96D43A36-8970-46E6-8DF4-0FA40E944EFC</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Munderi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950097146"><gtr:id>23F518AB-9120-40F5-9253-63A2B818597A</gtr:id><gtr:title>HIV Care Research Programme / ARROW trial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950097146</gtr:grantReference><gtr:abstractText>The treatment of HIV infection with anti-retroviral therapy (ART) has the potential to greatly improve the immune status of children and adults. In industrialised countries, ART provided is supported by routine laboratory tests to monitor whether the treatment is effective and safe. In Africa, routine laboratory support is usually not available and/or too expensive. As a result, ART in children is often managed based on clinical check-ups rather than with the help of laboratory data. Whilst the recently completed DART trial has shown that clinical driven monitoring is safe in adults, and that routine laboratory monitoring for toxicity is not required, these results cannot directly be applied to children without further research into the effectiveness and safety of this approach. The ARROW trial, conducted in about 1200 children in Uganda and Zimbabwe, is trying to address this question. The trial has also the aim to investigate whether ART is more effective if children receive the standard treatment with 3 different drugs plus a 4th drug during the first 9 months of treatment, or just a continuous therapy with 3 drugs only. Different combinations of the 4 drugs are explored.</gtr:abstractText><gtr:technicalSummary>The ARROW trial (Antiretroviral Research for Watoto) is A randomised multi-site trial of monitoring practice and induction maintenance drug regimens in the management of antiretroviral therapy (ART) in children in Africa. The Objectives are (1) to compare, in terms of HIV disease progression or death, routine laboratory monitoring (LCM) and clinically driven monitoring of ART (CDM); (2) to compare, in terms of long term effectiveness (immunological and clinical outcomes) 36 week induction of therapy with 4 ART drugs followed by maintenance using 3 drugs with a standard continuous triple drug ART regimen; (3) to address through separate sub-studies: the pharmacokinetics of antiretroviral drugs in children; the acceptability of and adherence to different antiretroviral drug formulations; the impact of malnutrition and nutritional supplementation; immune reconstitution syndromes in children; immunological and virological outcomes of ART in African children; metabolic complications of long term ART; and the cost benefits of the monitoring and induction maintenance approaches to ART in children. The design is an open, parallel group, randomised controlled clinical endpoint trial with a total duration of 5 years. At treatment initiation 1210 children (189 at MRC/UVRI Entebbe) were randomised 1:1 to the CDM or LCM monitoring strategy and to one of the following three 1st line ART regimens: Arm A (standard): NNRTI + ABC +3TC continuously Arm B (induction - maintenance): NNRTI + ZDV + ABC + 3TC for 36 weeks, then NNRTI + ABC +3TC Arm C (induction - maintenance): NNRTI + ZDV + ABC + 3TC for 36 weeks, then ZDV + ABC + 3TC Enrolment into the trial began in March 2007 and was completed in November 2008. Results of the ARROW trial are expected in late 2012. The trial is funded by the MRC, UK and the Department for International Development (UK). GlaxoSmithKline Ltd supply the drugs for the trial.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>648236</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Makerere University College of Health Sciences</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:department>The Infectious Diseases Institute, Kampala</gtr:department><gtr:description>Partnership with the Infectious Diseases Institute, Kampala</gtr:description><gtr:id>43370DA9-A0DE-4B1F-A7AC-8712AA8BFBC8</gtr:id><gtr:impact>Ongoing research and training collaboration and capacity to jointly implement future clinical studies in HIV care</gtr:impact><gtr:outcomeId>1E37411FD47-1</gtr:outcomeId><gtr:partnerContribution>Joint activities to implement a common clinical trial protocol. Joint scientific seminar and training activities</gtr:partnerContribution><gtr:piContribution>Contribution to scientific seminars and training activities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joint Clinical Research Center, Kampala</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Partnershipt iwth The Joint Clinical Research Centre, Kampala</gtr:description><gtr:id>F35EB414-3696-45F3-9934-92C5A7917A7D</gtr:id><gtr:impact>Established relationship and processes for future joint clinical studies in HIV care</gtr:impact><gtr:outcomeId>AB01104D33F-1</gtr:outcomeId><gtr:partnerContribution>Intersite collaboration on implementing the DART clinical study protocol. Provision of diagnostic laboratory services not available at MRC Entebbe Provision of post trial Antiretroviral therapy for DART study participants</gtr:partnerContribution><gtr:piContribution>Joint clinical study protocol implementation activities, including collaboration in virology and basic scince research activities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of the UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>Support from DfID</gtr:description><gtr:id>0307F161-22D9-421B-86CB-F16722EC62D4</gtr:id><gtr:impact>Health policy relevant clinical research results which are being disseminated to nationall and international health policy stakeholders</gtr:impact><gtr:outcomeId>C3BFB048CD3-1</gtr:outcomeId><gtr:partnerContribution>Support in dissemination of research findings to Health Policy stakeholders</gtr:partnerContribution><gtr:piContribution>Implentation of funded clinical trial protocol as per agreement, regular communication regarding progress and products of research, acknowledgement of organisational support at every dissemination forum.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation of Results to Uganda National ART Guidelines Committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3A190454-2E61-4B56-AD24-58DFCC21BE03</gtr:id><gtr:impact>A one day workshop where data generated in the ocuntry that are relevant for our national guideline revision. DART study results were a major contribution to the scientific data discussed by the national advisory panel.

DART study results will influence guidance on monitoring of ART in our next revision of the National guidelines</gtr:impact><gtr:outcomeId>p4LVTLFNgLa</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Uganda National Council of Science and Technology</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BAE8520B-D641-4E81-BC2A-A7BBE75EE36C</gtr:id><gtr:impact>National consultative meeting of research and medicines regulators to discuss ethical appropriateness of further trials on cotrimoxazole prophylaxis among HIV infected patients on antiretroviral therapy. We provided data on effect of Cotrimoxazole on haematologic parameters of untreated HIV infected adults.

A call was made for further studies evaluating continued prophylactic treatment with Cotrimoxazole for HIV infected patients on antiretroviral therapy</gtr:impact><gtr:outcomeId>95023512063</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Guidelines on Antiretroviral therapy in resource limited settings</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>FECB4115-EE9C-46CB-AFD3-1EBF6869D3C7</gtr:id><gtr:impact>Novel data on adverse events of specific antiretroviral drugs in an African population</gtr:impact><gtr:outcomeId>D8080F90012</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Uganda Ministry of Health - HIV Clinical Care Commitee</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>0AF91573-9EBC-454C-B3D9-3BD424F6BC65</gtr:id><gtr:impact>Development and revision of National antiretroviral therapy guidelines based on data from a research cohort in Uganda</gtr:impact><gtr:outcomeId>43A9143BA92</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4A5D1251-9615-4E72-B1DE-0593E48A2DC5</gtr:id><gtr:title>Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_16340_20_22972859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D42C75D3-B3FA-4F78-A538-F5FAEAD2E504</gtr:id><gtr:title>Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffb0f54dd45cee01098a90a4c4c9dac8"><gtr:id>ffb0f54dd45cee01098a90a4c4c9dac8</gtr:id><gtr:otherNames>Nahirya-Ntege P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>pm_16340_20_21164384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABD23ADF-5C96-4370-8D69-89A1793B78A5</gtr:id><gtr:title>Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e140361064e98cabc9d6bd78a2dabbe3"><gtr:id>e140361064e98cabc9d6bd78a2dabbe3</gtr:id><gtr:otherNames>ARROW Trial team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_16340_20_23473847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53B1E3A5-AE11-4B3E-B84E-203FE0791B16</gtr:id><gtr:title>Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e3d78c5672e7bdca46d5ced1d2d76a0"><gtr:id>0e3d78c5672e7bdca46d5ced1d2d76a0</gtr:id><gtr:otherNames>Musiime V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>pm_16340_20_23407100</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U950097146</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>B7F5A9CA-62C7-4E68-A2B2-3D6CCA85E16B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>7.3  Management and decision making</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>